Profile change history

What changed for Pemvidutide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Pemvidutide identity.

8Total events
6Record additions
2Version changes
2Cited source years

Before and after

Preserved version changes

Profile status changed

Pemvidutide profile

We added a plain-language reader guide with cited answers, IMPACT trial results from our human evidence review, and retained ClinicalTrials.gov records for later trials, including a Phase 3 trial in MASH.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
Investigational
After
In clinical trials; not FDA-approved

Profile summary

Before
A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
After
An experimental Altimmune glucagon and GLP-1 receptor agonist studied in the liver disease MASH. It is not FDA-approved.

Evidence note

Before
ClinicalTrials.gov lists Altimmune's IMPACT study as completed, last updated May 18, 2026.
After
A 24-week randomized Phase 2 trial met its MASH-resolution goal but not its fibrosis goal. A Phase 3 trial in MASH was recruiting in August 2026.

Cited source records

Before
ctg-nct05989711-v10
After
ctg-nct05989711-v10, journal-pmid-41237796, ctg-observation-nct07795164-2026-08-31-445923515599, ctg-observation-nct06987513-2026-07-31-1e0339600b69, ctg-observation-nct07009860-2026-03-20-c02a1977625c

Claim citations

Before
name: ctg-nct05989711-v10; aliases: ctg-nct05989711-v10; category: ctg-nct05989711-v10; status: ctg-nct05989711-v10; summary: ctg-nct05989711-v10; evidenceNote: ctg-nct05989711-v10
After
name: ctg-nct05989711-v10; aliases: ctg-nct05989711-v10; category: ctg-nct05989711-v10; status: ctg-nct05989711-v10, ctg-observation-nct07795164-2026-08-31-445923515599; summary: ctg-nct05989711-v10, journal-pmid-41237796; evidenceNote: journal-pmid-41237796, ctg-observation-nct07795164-2026-08-31-445923515599
Profile updated

Pemvidutide profile

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
A glucagon/GLP-1 receptor agonist candidate with trial-registry records.
After
A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.

Collection chronology

Evidence added to PeptideScanner

Browse all 6 connected records →

Showing the latest 6 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: September 9, 2026.

Record added

ClinicalTrials.gov record NCT04561245

PeptideScanner retained ClinicalTrials.gov record NCT04561245 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-24, and PeptideScanner's reviewed identity mapping was pemvidutide.

PeptideScanner change date
September 9, 2026
Cited source date
June 24, 2025
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07795164

PeptideScanner retained ClinicalTrials.gov record NCT07795164 at 2026-09-09T19:17:17.076Z. Its registry update date was 2026-08-31, and PeptideScanner's reviewed identity mapping was pemvidutide.

PeptideScanner change date
September 9, 2026
Cited source date
August 31, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06987513

PeptideScanner retained ClinicalTrials.gov record NCT06987513 at 2026-08-10T18:10:03.928Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was pemvidutide.

PeptideScanner change date
August 14, 2026
Cited source date
July 31, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07009860

PeptideScanner retained ClinicalTrials.gov record NCT07009860 at 2026-07-30T16:22:22.335Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was pemvidutide.

PeptideScanner change date
August 14, 2026
Cited source date
March 20, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05989711

PeptideScanner retained ClinicalTrials.gov record NCT05989711 at 2026-07-30T16:19:36.923Z. Its registry update date was 2026-05-18, and PeptideScanner's reviewed identity mapping was pemvidutide.

PeptideScanner change date
August 9, 2026
Cited source date
May 18, 2026
Evidence lane
Clinical trials